Overview

Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer

Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
This study is designed to determine the safety and highest tolerated dose of anti-OX40 in patients with advanced cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Providence Health & Services
Treatments:
Vaccines